EAR Apr 2023 0.500 put
| Previous close | 0.1500 |
| Open | 0.1400 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 0.50 |
| Expiry date | 2023-04-21 |
| Day's range | 0.1400 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- GlobeNewswire
Eargo Reports Fourth Quarter 2022 Financial Results
Recent Highlights: Net revenues of $12.9 million in the fourth quarter of 2022, compared to $10.1 million in the fourth quarter of 2021 and $7.9 million in the third quarter of 2022Gross systems shipped of 8,863, compared to 7,767 in the fourth quarter of 2021GAAP operating loss $23.9 million in the fourth quarter of 2022, compared to $45.2 million in the fourth quarter of 2021 and $26.0 million in the third quarter of 2022Cash and cash equivalents of $101.2 million as of December 31, 2022Prior
- GlobeNewswire
Eargo to Report Fourth Quarter 2022 Financial Results on March 23, 2023
SAN JOSE, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the fourth quarter 2022 after market close on March 23, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing
- GlobeNewswire
Nasdaq Confirms Eargo’s Minimum Bid Price Deficiency is Cured
SAN JOSE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (the “Company” or “Eargo”), a medical device company on a mission to improve the quality of life of people with hearing loss, announced today that it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) dated February 1, 2023 informing Eargo that the Company’s minimum bid price deficiency has been cured. The letter from Nasdaq follows the Company’s 1-for-20 reverse stock split approved by stockholders on Octob
